Cogint, Inc.
News
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
Simply Wall St There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...\n more…
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCOGT stock results show that Cogent Biosciences missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…
Cogent Biosciences (COGT) Receives a Buy from Jefferies
TipRanks Financial Blog Jefferies analyst Kelly Shi maintained a Buy rating on Cogent Biosciences (COGT - Research Report) today and set a price target of $20.00. The comp...\n more…
Buy Rating Affirmed for Cogent Biosciences Amidst Positive Clinical Trial Progress and Regulatory Milestones
TipRanks Financial Blog Needham analyst Ami Fadia has maintained their bullish stance on COGT stock, giving a Buy rating on June 17. Ami Fadia has given his Buy rating due...\n more…
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial
Globe Newswire Enrollment in SUMMIT Part 2 remains on track for completion in Q2 2025 with top-line results expected by end of 2025WALTHAM, Mass. and BOULDER, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Cogent...\n more…
Cogent Biosciences: Inflection Year Directly Ahead
SeekingAlpha Cogent Biosciences: Inflection Year Directly Ahead...\n more…